Colorectal cancer (CRC) is one of the most common malignancies with high prevalence and
low 5-year survival. CRC is a heterogeneous disease with a complex, genetic and …

Colorectal cancer (CRC) is the third most common diagnosed malignancy among both
sexes in the United States as well as in the European Union. While the incidence and …

The p53 tumour suppressor is modified through mutation or changes in expression in most
cancers, leading to the altered regulation of hundreds of genes that are directly influenced …

Most of the colorectal cancer (CRC) cases are sporadic, only 25% of the patients have a
family history of the disease, and major genes causing syndromes predisposing to CRC only …

The initial observation that p53 accumulation might serve as a surrogate biomarker for TP53
mutation has been the cornerstone for vast translational efforts aimed at validating its clinical …

Colorectal cancer is a multifaceted disease which is therapeutically challenging. Based on
insights gleaned from almost a quarter century of research, it is obvious that deregulation of …

Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide.
Several genome sequencing studies have provided comprehensive CRC genomic datasets …

Abstract p53, p63 and p73 are members of the p53 gene family involved in development,
differentiation and response to cellular stress. p53 gene is a transcription factor essential for …

Colorectal cancer (CRC) is a biologically heterogeneous disease. To characterize its
mutational profile, we conduct targeted sequencing of 205 genes for 2,105 CRC cases with …

Piwi‐interacting RNA s (pi RNA s), a novel class of small non‐coding RNA s, were first
discovered in germline cells and are thought to silence transposons in spermatogenesis …